FLAM
RARE icon

First Light Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

First Light Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-285,699
Closed -$8.59M – 40
2025
Q3 		$8.59M Sell
285,699
-262,206
-48% -$7.86M 0.81% 31
2025
Q2 		$19.9M Sell
547,905
-84,128
-13% -$3.03M 2.58% 14
2025
Q1 		$22.9M Sell
632,033
-131,574
-17% -$5.47M 2.61% 14
2024
Q4 		$32.1M Buy
763,607
+8,505
+1% +$422K 3.07% 15
2024
Q3 		$41.9M Sell
755,102
-208,044
-22% -$10.6M 3.49% 12
2024
Q2 		$39.6M Buy
963,146
+172,700
+22% +$7.37M 3.47% 11
2024
Q1 		$36.9M Buy
790,446
+45,781
+6% +$2.16M 2.83% 14
2023
Q4 		$35.6M Sell
744,665
-380,367
-34% -$14.7M 2.86% 14
2023
Q3 		$40.1M Buy
1,125,032
+535,069
+91% +$21.2M 3.81% 9
2023
Q2 		$27.2M Buy
589,963
+354,186
+150% +$16.4M 2.13% 16
2023
Q1 		$9.45M Buy
235,777
+1,478
+0.6% +$63.4K 0.85% 33
2022
Q4 		$10.9M Sell
234,299
-219,495
-48% -$8.63M 1.01% 33
2022
Q3 		$18.8M Buy
453,794
+1,324
+0.3% +$68K 1.9% 22
2022
Q2 		$27M Buy
452,470
+14,958
+3% +$920K 3.14% 10
2022
Q1 		$31.8M Buy
437,512
+26,199
+6% +$1.82M 2.8% 12
2021
Q4 		$34.6M Sell
411,313
-29,846
-7% -$2.43M 2.48% 13
2021
Q3 		$39.8M Buy
441,159
+211,913
+92% +$19.2M 2.62% 13
2021
Q2 		$21.9M Buy
229,246
+11,787
+5% +$1.23M 1.31% 31
2021
Q1 		$24.8M Buy
217,459
+3,572
+2% +$486K 1.64% 24
2020
Q4 		$29.6M Buy
213,887
+28,917
+16% +$3.43M 2.19% 16
2020
Q3 		$15.2M Sell
184,970
-51,988
-22% -$4.31M 1.56% 22
2020
Q2 		$18.5M Sell
236,958
-105,645
-31% -$6.99M 2.16% 19
2020
Q1 		$15.2M Buy
342,603
+168,166
+96% +$8.73M 2.6% 19
2019
Q4 		$7.45M Sell
174,437
-5,222
-3% -$215K 0.95% 28
2019
Q3 		$7.69M Sell
179,659
-358
-0.2% -$19.4K 1.16% 27
2019
Q2 		$11.4M Buy
+180,017
New +$11.5M 1.59% 24

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Light Asset Management's RARE Position: Q4 2025 in Review

First Light Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 285,699 shares — an estimated $8.59M sold.

First Light Asset Management first reported a position in RARE in Q2 2019 and held it in 26 quarters. The position peaked at $41.9M in Q3 2024. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • First Light Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • First Light Asset Management sold 285,699 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $8.59M.
  • First Light Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2019 and held it in 26 quarters.
  • First Light Asset Management's Ultragenyx Pharmaceutical position peaked at $41.9M in Q3 2024.
  • 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on First Light Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.